Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Medigen Biotechnology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -160.79%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medigen Biotechnology's 3-Year ROIIC % or its related term are showing as below:
ROCO:3176's 3-Year ROIIC % is ranked worse than 77.2% of 1320
companies
in the Biotechnology industry
Industry Median: -4.82
vs ROCO:3176: -160.79
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medigen Biotechnology 3-Year ROIIC % Related Terms
Medigen Biotechnology 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Medigen Biotechnology's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's 3-Year ROIIC % falls into.
Medigen Biotechnology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -105.027 (Dec. 2025) - -1645.843 (Dec. 2022) )
/
( 3353.819 (Dec. 2025) - 4312.085 (Dec. 2022) )
=
1540.816
/
-958.266
=
-160.79%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medigen Biotechnology (ROCO:3176) has a 3-Year ROIIC % of -160.79 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medigen Biotechnology and its competitors. According to the industry distribution chart, Medigen Biotechnology ranks #1019 out of 1320 companies in the Biotechnology industry, placing it in the top 77.2%.
Is Medigen Biotechnology's 3-Year ROIIC % too high?
Medigen Biotechnology's current 3-Year ROIIC % is -160.79. Based on the distribution chart, Medigen Biotechnology ranks #1019 out of 1320 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medigen Biotechnology has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #1019 out of 1320 companies for 3-Year ROIIC %. This places Medigen Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current 3-Year ROIIC % is -160.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$36.82, compared to a current price of NT$31.65 — trading 14% below its estimated fair value. The current 3-Year ROIIC % is -160.79. Medigen Biotechnology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current 3-Year ROIIC % is -160.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$31.65 is trading 14% below its estimated GF Value™ of NT$36.82.
GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3176:
3-Year ROIIC %: -160.79
GF Value™: NT$36.82 vs. price of NT$31.65 (14% below fair value)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
55GF Score
Get the complete analysis for ROCO:3176
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
